Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine, Inc., Announces Proposed Offering of Common Stock

GlobeNewswire March 15, 2017

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

GlobeNewswire March 14, 2017

Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update

GlobeNewswire March 7, 2017

Editas Medicine Announces Departure of Chief Operating Officer

GlobeNewswire March 3, 2017

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results

GlobeNewswire February 28, 2017

Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017

GlobeNewswire February 28, 2017

Editas Medicine to Present at Investor Conferences in March

GlobeNewswire February 27, 2017

Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference

GlobeNewswire February 15, 2017

Editas Medicine to Present at Upcoming February Investor Conferences

GlobeNewswire February 10, 2017

Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

GlobeNewswire January 9, 2017

Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2017

Flagship Ventures Evolves Name To Flagship Pioneering

PR Newswire December 15, 2016

Editas Medicine to Present at the Stifel Healthcare Conference 2016

GlobeNewswire November 9, 2016

Editas Medicine Announces Third Quarter 2016 Results and Update

GlobeNewswire November 7, 2016

Editas Medicine to Host Conference Call Discussing Third Quarter 2016 Corporate Update and Results

GlobeNewswire October 31, 2016

Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016

GlobeNewswire October 17, 2016

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

GlobeNewswire October 6, 2016

Editas Medicine to Present at the Jefferies Gene Editing/Therapy Summit

GlobeNewswire October 3, 2016

Editas Medicine Expands Senior Management Team

GlobeNewswire October 3, 2016

Editas Medicine to Present at the Morgan Stanley Global Healthcare Conference

GlobeNewswire September 6, 2016